New Releases from NCBI BookshelfAtezolizumab for untreated PD-L1-positive advanced urothelial cancer when cisplatin is unsuitable.​Atezolizumab for untreated PD-L1-positive advanced urothelial cancer when cisplatin is unsuitable.